The global immunoprotein diagnostic testing market size was valued at USD 5.8 billion in 2016 and is expected to witness lucrative growth from 2017 to 2025, projects Grand View Research. High prevalence of chronic disorders, such as infectious diseases, cancer, cardiovascular disease, obesity, type II diabetes, and rheumatoid arthritis has led to growth of immunoprotein diagnostic testing products. Increasing mortality due to such chronic diseases has led to an urgent need for rapid diagnosis.

Based on technology, enzyme-based immunoassay (EIA) held the largest market share in 2016. It can be used as a diagnostic tool as well as a quality control tool in numerous companies and laboratories. Moreover, majority of the key companies have an extensive portfolio of analyzers with EIA technology. Chemiluminescence assay is expected to exhibit highest growth over the years due to its high specificity and sensitivity as well as ability to detect antigens in human serum and plasma samples. This technology minimizes any interruption in workflow of the system and enables on-board reagent capacity to reduce turnaround time.

In 2016, North America dominated the market due to well-established healthcare infrastructure, which has led to an increase in adoption of immunoprotein diagnostic instruments in laboratories and diagnostic centers. Moreover, high incidence of cancer among the US population also led to the growth of this market. APAC is expected to witness highest growth over the years owing to extremely rapid economic development coupled with rapid evolvement of the medical healthcare system in countries such as China and India. Collaboration between public health institutions in China, such as Ministry of Health and China CDC, and the U.S. CDC, focused on Chinese healthcare structure pertaining to HIV/AIDS, immunizations, emerging infectious diseases, noncommunicable diseases, and laboratory quality control has also led to the growth in this region.

Some of the key companies in the global market are Abbott Laboratories, Bio-Rad Laboratories Inc., DiaSorin S.p.A, Enzo Biochem Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., bioMrieux SA, Abcam Plc, Siemens Healthcare GmbH, Beckman Coulter, and Ortho Clinical Diagnostics. Major strategies undertaken by these key players include new product development, M&A, strategic partnerships, and geographical expansions. For instance, in May 2016, DiaSorin acquired the immunodiagnostic and molecular diagnostic products of Focus Diagnostics from Quest Diagnostics. In June 2016, Ortho Clinical Diagnostics and Beckman Coulter entered into a strategic partnership for sales of Ortho's VITROS 3600 Immunodiagnostic System and portfolio for infectious diseases in the United States.

10 Diagnostic Imaging Trends for 2018



Digital version